Technical Analysis for PGNX - Progenics Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade D 4.1 -9.39% -0.43
PGNX closed down 9.39 percent on Friday, June 19, 2020, on 25.17 times normal volume. It was able to find support at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down
Historical PGNX trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Bearish Engulfing Bearish 0.00%
Fell Below 20 DMA Bearish 0.00%
50 DMA Support Bullish 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
Outside Day Range Expansion 0.00%
Upper Bollinger Band Touch Strength 0.00%
20 DMA Support Bullish -9.39%
Pocket Pivot Bullish Swing Setup -9.39%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Progenics Pharmaceuticals, Inc. engages in the research and development of biotechnology product candidates in the areas of oncology and therapeutics worldwide. The company offers RELISTOR (methylnaltrexone bromide), a subcutaneous injection for the treatment of opioid induced constipation (OIC) in patients with advanced illnesses, such as cancer, as well as for the treatment of OIC in patients with non-cancer pain; and RELISTOR-Oral, which has completed Phase III testing for the treatment of OIC in patients with non-cancer pain. It also provides oncology medicines, including PSMA ADC that is in Phase II testing for treatment of prostate and other cancers; and MIP-1404, which is in Phase II testing for imaging agent for prostate cancer; and Azedra for the treatment of pheochromocytoma and paraganglioma, and Neuroblastoma. PSMA ADC is an antibody-drug conjugate (ADC) that targets prostate specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells, as well as on the neovasculature of various other types of solid tumors. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of RELISTOR worldwide other than Japan. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.
Medicine Chemistry Biotechnology Cancer Pain Imaging Oncology Solid Tumors Cancers Prostate Cancer Morphinans Neuroblastoma Phenols Cyclopropanes Adc Constipation Salix Pharmaceuticals

Is PGNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.37
52 Week Low 1.89
Average Volume 1,387,661
200-Day Moving Average 4.61
50-Day Moving Average 4.05
20-Day Moving Average 4.30
10-Day Moving Average 4.34
Average True Range 0.35
ADX 16.43
+DI 21.25
-DI 22.11
Chandelier Exit (Long, 3 ATRs ) 3.79
Chandelier Exit (Short, 3 ATRs ) 4.76
Upper Bollinger Band 4.74
Lower Bollinger Band 3.86
Percent B (%b) 0.27
BandWidth 20.47
MACD Line 0.09
MACD Signal Line 0.11
MACD Histogram -0.0282
Fundamentals Value
Market Cap 288.1 Million
Num Shares 70.3 Million
EPS -0.06
Price-to-Earnings (P/E) Ratio -68.33
Price-to-Sales 6.47
Price-to-Book 5.52
PEG Ratio -0.02
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.38
Resistance 3 (R3) 5.46 5.13 5.16
Resistance 2 (R2) 5.13 4.80 5.08 5.09
Resistance 1 (R1) 4.61 4.60 4.45 4.53 5.02
Pivot Point 4.28 4.28 4.19 4.23 4.28
Support 1 (S1) 3.76 3.95 3.60 3.68 3.18
Support 2 (S2) 3.43 3.75 3.38 3.11
Support 3 (S3) 2.91 3.43 3.04
Support 4 (S4) 2.83